1. Suven Life Sciences shares gain on securing 7 new product patents

Suven Life Sciences shares gain on securing 7 new product patents

Suven Life shares gained after it informed BSE that it has secured 7 product patents for their New Chemical Entities in ARIPO, Europe, Hong Kong, Japan, Macau and South Korea.

By: | New Delhi | Updated: December 23, 2015 5:05 PM
Suven Life Sciences share price, Sensex

Suven Life shares gained after it informed BSE that it has secured 7 product patents for their New Chemical Entities in ARIPO, Europe, Hong Kong, Japan, Macau and South Korea. (Photo: PTI)

Suven Life Sciences shares gained as much as 6.72 per cent in the morning trade on Wednesday after the biopharmaceutical company informed BSE that it has secured 7 product patents for their New Chemical Entities in ARIPO, Europe, Hong Kong, Japan, Macau and South Korea.

At 11.53 am, the share price of Suven Life Sciences was trading 4.71 per cent up at Rs 267.65. The scrip opened at Rs 255 and had touched a high and low of Rs 272.80 and Rs 255, respectively in trade so far. Later, the scrip settled 3.87 per cent up at Rs 265.50.

In a BSE filing, the company said, “The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of coginitive impairment associated with neurodegenerative disorders.”

With these new patents, Suven has a total of one granted product patent in ARIPO, 19 granted patents from Europe, 18 granted patents from Hong Kong, 18 granted patents from Japan, seven patents from Macau and 18 granted patents from South Korea.

“These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II,” said Suven Life Sciences in a BSE filing.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets

  1. No Comments.

Go to Top